First Manhattan’s Editas Medicine EDIT Stock Holding History

First Manhattan’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-43	Closed	-$319	–	839
2024 Q1	$319	Hold	43	–	–	﹤0.01%	1364
2023 Q4	$435	Sell	43 -400	-90%	-$3.51K	﹤0.01%	1363
2023 Q3	$3.46K	Hold	443	–	–	﹤0.01%	1273
2023 Q2	$3.65K	Hold	443	–	–	﹤0.01%	1258
2023 Q1	$3.21K	Hold	443	–	–	﹤0.01%	1347
2022 Q4	$3.93K	Hold	443	–	–	﹤0.01%	1457
2022 Q3	$5K	Hold	443	–	–	﹤0.01%	1304
2022 Q2	$5K	Hold	443	–	–	﹤0.01%	1329
2022 Q1	$8K	Buy	443 +100	+29%	+$1.86K	﹤0.01%	1312
2021 Q4	$9K	Buy	343 +100	+41%	+$3.44K	﹤0.01%	1301
2021 Q3	$9K	Buy	243 +43	+22%	+$2.36K	﹤0.01%	1298
2021 Q2	$11K	Hold	200	–	–	﹤0.01%	1259
2021 Q1	$8K	Hold	200	–	–	﹤0.01%	1267
2020 Q4	$14K	Hold	200	–	–	﹤0.01%	1106
2020 Q3	$5K	Hold	200	–	–	﹤0.01%	1195
2020 Q2	$5K	Hold	200	–	–	﹤0.01%	1239
2020 Q1	$3K	Buy	+200	New	+$5.04K	﹤0.01%	1269
2016 Q2	–	Sell	-500	Closed	-$17K	–	1472
2016 Q1	$17K	Buy	+500	New	+$13.1K	﹤0.01%	1085

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

First Manhattan's EDIT Position: Q2 2024 in Review

First Manhattan sold out of Editas Medicine (EDIT) in Q2 2024, closing a stake of 43 shares — an estimated $319 sold.

First Manhattan first reported a position in EDIT in Q1 2016 and held it in 18 quarters. The position peaked at $17K in Q1 2016. 235 funds tracked by Wall St. Rank hold EDIT as of Q2 2024.

First Manhattan reported no remaining Editas Medicine position as of Q2 2024 after selling out during the quarter.
First Manhattan sold 43 Editas Medicine shares in Q2 2024, an estimated $319.
First Manhattan first reported a position in Editas Medicine in Q1 2016 and held it in 18 quarters.
First Manhattan's Editas Medicine position peaked at $17K in Q1 2016.
235 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2024.

Based on First Manhattan's 13F filing for Q2 2024, filed 14 Aug 2024.